Evaluation of a Pilot: Inspection Facilitation and Collaboration Using a Mixed Reality Device

Author:

Baker Peter,Cathey Tamika,Auclair Jared R.ORCID

Abstract

AbstractThe COVID-19 pandemic forced industry and national regulatory authorities (NRAs) to think about innovative ways to ensure business continuity, including Good Manufacturing Practices (GMP) inspections. Even prior to COVID-19, it was understood that GMP site inspections, especially redundant inspections, are a time and resource-intensive process for both industry and regulators in high-income countries and often prohibitive to resource-challenged countries. Thus, we investigated the use of a mixed reality device and Microsoft (MS) Teams as a platform for mixed reality (hybrid) remote inspection. This pilot involved a mock GMP inspection of a drug manufacturing facility in the United States. The mock inspection was conducted by two former USFDA (US Food and Drug Administration) investigators, facilitated by representatives from Northeastern University along with The Bill and Melinda Gates Foundation. Also participating in the inspection were inspectors from national regulatory agencies (NRAs) from the African continent, including Nigeria, South Africa, Uganda, and Zimbabwe, and representatives from the Pre-Qualification Inspection Unit at the World Health Organization (WHO). Harmonized inspectional guidance from PIC/s (GMP Guide) and WHO (TRS 823) were used as the standards for conducting the mock inspection. We found that mixed reality, used in conjunction with a collaborative text messaging system, is a viable tool to facilitate remote inspections and allows inspectors participating remotely to write their own independent inspection reports.

Funder

Bill and Melinda Gates Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference13 articles.

1. cGMP in Manufacturing, Processing, Packaging, or Holding of Drugs and Finished Pharmaceuticals. 2021.

2. Yu LX, Woodcock J. FDA pharmaceutical quality oversight. Int J Pharm. 2015;491(1–2):2–7.

3. A New World for Pharmaceutical Inspections The Mutal Recognition Agreement. US FDA Foreign GMP Inspection; 2023.

4. Tirivangani T, Alpo B, Kibuule D, Gaeseb J, Adenuga BA. Impact of COVID-19 pandemic on pharmaceutical systems and supply chain—a phenomenological study. Explor Res Clin Soc Pharm. 2021;2: 100037.

5. Information Sharing. 2018. https://www.fda.gov/federal-state-local-tribal-and-territorial-officials/communications-outreach/information-sharing

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3